替吉奥联合奈达铂治疗晚期食管癌的临床研究

Clinical study on S-1 combined with nedaplatin for patients with advanced esophageal cancer

目的评价国产替吉奥联合奈达铂治疗晚期食管癌的有效性及安全性。方法 56例晚期食管癌患者随机分为治疗组和对照组,各组28例。治疗组:替吉奥口服+奈达铂静脉滴注。对照组:亚叶酸钙+氟尿嘧啶+顺铂静脉滴注。3周期后评价疗效及不良反应。结果入组病例均可评价疗效和不良反应,治疗组和对照组的有效率分别为57.1%和42.9%,差异具有统计学意义。除Ⅲ级血小板减少外,治疗组的不良反应及严重不良反应发生率均低于对照组。结论替吉奥联合奈达铂治疗晚期食管癌治疗有效率高,耐受性良好,值得临床推广。

Objective To evaluate the efficacy and safety of S-1 plus nedaplatin in the treatment of patients with advanced esophageal cancer.Methods Fifty-six cases with advanced esophageal cancer were randomly divided into treatment and control groups with 28 each.The treatment group received S-1＋nedaplatin（intravenous infusion）,while the control group received calcium folinate ＋ fluorouracil ＋ cisplatin（intravenous infusion）.Short-term efficacy and adverse reactions were evaluated after 3 cycles.Results The efficacy and adverse events in both groups could be evaluated.The efficacy rates of the treatment group and the control group were 57.1% and 42.9%,respectively.The difference between two groups was statistically significant.Compared with the control group,the incidence rates of adverse reactions and serious reactions in the treatment group were apparently lower except the decrease in the number of Level Ⅲ platelets.Conclusion The regimen of S-1 combined with nedaplatin shows good efficacy in the treatment of advanced esophageal cancer with good tolerance.Thus it is worthy of clinical applications.